Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

CGP 74514A

CDK/cyclin inhibitor
 
ALX-270-391-M005 5 mg 82.00 USD
 
ALX-270-391-M025 25 mg 279.00 USD
Do you need bulk/larger quantities?
 
Cell permeable, potent and selective inhibitor of CDK1/cyclin B (IC50=25nM). Reported to affect the activities of other kinases only at much higher concentrations: PKCα (IC50=6.1µM), PKA (IC50=125µM) and EGFR (IC50>10µM). Induces mitochondrial damage and apoptosis in several human leukemia cell lines (>3µM).

Product Specification

Alternative Name:N-(cis-2-Aminocyclohexyl)-N-(3-chlorophenyl)-9-ethyl-9H-purine-2,6-diamine
 
Formula:C19H24ClN7
 
MW:385.9
 
Purity:≥95% (HPLC)
 
Appearance:White to yellow solid.
 
Solubility:Soluble in DMSO.
 
Shipping:Ambient
 
Long Term Storage:-20°C
 
Handling:Protect from light. Packaged under inert gas.
 
270-391
Please mouse over
270-391

Product Literature References

The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process: C. Yu, et al.; Cancer Res. 63, 1822 (2003), Abstract;
2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors: P. Imbach, et al.; Bioorg. Med. Chem. Lett. 9, 91 (1999), Abstract;

Related Literature

Product Flyers
Cell Cycle - Mitosis, CDKS & Cell Cycle Signaling
Cell Cycle - Mitosis, CDKS & Cell Cycle Signaling
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,